Figure 1. Study Schema

Assessment of Patient Eligibility

Consent and Patient Enrolment

Baseline Clinical Assessment (within 14 days prior to initiation of treatment)

Randomization

HBOT (active) + Standard care for 6 weeks

HBOT (placebo) + Standard care for 6 weeks

Follow-up assessments every week from week 6 to week 12 from initiation of treatment

Follow-up telephone interviews at weeks 30 and 52